Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23729307 | 0.97 | NAMPT (0.47) | CASP2NAMPTTSHRLMNAPKM | |
| SCHEMBL26700952 | 0.97 | NAMPT (0.47) | CASP2NAMPTTSHRLMNAPKM | |
| SCHEMBL13599210 | 0.97 | NAMPT (0.47) | CASP2NAMPTTSHRLMNAPKM | |
| SCHEMBL26700954 | 0.97 | NAMPT (0.47) | CASP2NAMPTTSHRLMNAPKM | |
| SCHEMBL16248541 | 0.97 | NAMPT (0.47) | CASP2NAMPTTSHRLMNAPKM | |
| SCHEMBL26700957 | 0.95 | NAMPT (0.45) | CASP2NAMPTTSHRLMNAPKM | |
| SCHEMBL24935691 | 0.93 | NAMPT (0.47) | CASP2NAMPTTSHRLMNAPKM | |
| SCHEMBL21029751 | 0.92 | NAMPT (0.45) | CASP2NAMPTTSHRLMNAPKM | |
| SCHEMBL26818739 | 0.92 | LMNA (0.44) | CASP2NAMPTTSHRLMNAPKM | |
| SCHEMBL16689670 | 0.88 | LMNA (0.54) | NAMPTTSHRLMNAPKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-9714421-B2 | Compositions and methods | IONIS PHARMACEUTICALS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-9382540-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | ISIS PHARMACEUTICALS, INC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160090596-A1 | COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-31 | — | — | US | disclosed |
| US-20160076032-A1 | COMPOSITIONS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160017323-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | CASP2 4544/4885NAMPT 407/4885TSHR 370/4885 |
| US-20170043025-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ACOT7, COASY, LCAT | CASP2 3774/4885NAMPT 1508/4885TSHR 1805/4885 |
| US-20160076032-A1 | COMPOSITIONS AND METHODS | FUT6, FUT5, GNE | CASP2 4371/4885NAMPT 233/4885TSHR 4110/4885 |
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | CASP2 4102/4885NAMPT 164/4885TSHR 2899/4885 |
| US-20150176007-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | CASP2 4345/4885NAMPT 722/4885TSHR 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.